Q4-FY26 · Nirav Mehta
We expect to sustain 15% plus revenue growth organically and 25% revenue growth in acquired brand with 20% plus PAT growth in FY27.
CORONAREMEDIES / language trends
Read confidence between the lines.
Corona Remedies · tone and specificity signals across the available quarters.
Research layer active
Language signals
What changed in management language.
tracked
Q4-FY26 · Bhavin Bhagat
Our revenue growth in FY26 was driven by a 3% increase in volumes significantly outpacing the IPM of 0.7% volume growth by nearly 4.6 times.
Q4-FY26 · Nirav Mehta
Semaglutide brings a new dimension to the diabetic market as well as obesity market and generic semaglutide market has been exciting for sure.